[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 23, 1988

Primary Prevention With Metoprolol in Patients With Hypertension

Author Affiliations

University of South Florida College of Medicine Tampa General Hospital

University of South Florida College of Medicine Tampa General Hospital

JAMA. 1988;260(12):1715. doi:10.1001/jama.1988.03410120059018
Abstract

To the Editor.—  The results of the Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) Study,1 showing lower mortality with metoprolol use compared with thiazide diuretic therapy, is concordant with many of our beliefs that thiazides are potentially harmful while β-blockers may be cardioprotective. The MAPHY Study, by Wikstrand et al, used neither a placebo group nor actuarial data. As such, three possibilities exist. β-Blockers may be mortality neutral while diuretics have increased mortality, β-blockers may be cardioprotective while diuretics are mortality neutral, or β-blockers are cardioprotective and diuretics have increased mortality. In a previous study by Morgan et al,2 moderately hypertensive men were treated with either placebo, low-salt diet, high-dose thiazide, or β-blocker. When compared with actuarial data there were twice as many deaths than predicted in the diuretic-treated group and expected numbers of deaths in all other groups. In the study by Wikstrand et al it is clear

×